Advertisement

 

 

Lenvatinib – A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.

Lenvatinib – A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.
Author Information (click to view)

Hewett Y, Ghimire S, Farooqi B, Shah BK,


Hewett Y, Ghimire S, Farooqi B, Shah BK, (click to view)

Hewett Y, Ghimire S, Farooqi B, Shah BK,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2016 11 1824(1) 28-32 doi 10.1177/1078155216680119

Abstract

Lenvatinib, an oral multikinase inhibitor, was approved by the US Food and Drug Administration in February 2015. In a pivotal phase III study of 392 patients with progressive radioiodine-refractory thyroid cancer, the overall response rate of patients receiving lenvatinib was 64.8%, with complete response in four patients. The median progression-free survival was 18.3 months in the lenvatinib arm versus 3.6 months in patients receiving placebo. Median overall survival was not reached in either arm. Lenvatinib is a promising new treatment for patients with radioiodine (iodine-131)-refractory differentiated thyroid cancer.

Submit a Comment

Your email address will not be published. Required fields are marked *

17 − two =

[ HIDE/SHOW ]